Peng Xiao

机构：Qingdao University, Tianjin University of Science and Technology, Tianjin University of Technology, Shanxi Medical University, Sir Run Run Shaw Hospital, Yuhuangding Hospital, Third People's Hospital of Chengdu, Zhejiang Center for Disease Control and Prevention, Southwest Jiaotong University, Chengdu University of Traditional Chinese Medicine, Zhejiang University, University of Louisiana at Lafayette · ORCID：0000-0002-5308-8400

发表论文 102 篇 · 总被引 2957 次 · h-index 24

代表论文

• Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity (2022 · Science Translational Medicine · 被引 114)
• Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial (2022 · Nature Communications · 被引 45)
• Intranasal parainfluenza virus type 5 (PIV5)–vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study (2023 · Science Advances · 被引 38)
• Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial (2022 · Signal Transduction and Targeted Therapy · 被引 31)
• Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin/monophosphoryl lipid A nanoparticle (2024 · PNAS Nexus · 被引 13)
• Anti-human immunodeficiency virus-1 activity of MoMo30 protein isolated from the traditional African medicinal plant Momordica balsamina (2023 · Virology Journal · 被引 12)